Clinical Trial Update: Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating daratumumab in relapsed or high-risk myeloid malignancies (high-risk myelodysplastic syndrome and recurrent/refractory acute myeloid le…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• High-risk Myelodysplastic Syndrome

Drugs mentioned

• Daratumumab (daratumumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2023-09-21